アブカムでは最適な動作のために Google Chrome など最新ブラウザでの閲覧を推奨します。

私たちはウェブサイトをできるだけ使いやすくするために、クッキーを使用しています。

クッキー・ポリシーでは、使用するクッキーをオプトアウトする方法について説明しています。

クッキーの設定を変更しないままでいる場合、このポリシーに同意しているとみなされます。

続ける 続ける

お問い合わせは電話 +81-(0)3-6231-0940 または メールでどうぞ

  • アカウント
  • ログアウト
ログイン または 新規登録

Welcome

ログイン または

すでにアカウントをお持ちですか?

新規登録
カート
クイック・オーダー
Abcam homepage

  • 研究用製品
    製品タイプ別
    一次抗体
    二次抗体
    イムノアッセイキット・試薬
    細胞・組織イメージング
    細胞・バイオケミカルアッセイ
    タンパク質・ペプチド
    製品タイプ別
    プロテオミクス
    アゴニスト・アクチベータ-・アンタゴニスト・インヒビター
    細胞株・ライゼート
    miRNA マルチプレックス・アッセイキット
    マルチプレックス・アッセイ
    研究分野別
    癌
    循環器系
    細胞生物学
    エピジェネティクス
    メタボリズム
    発生生物学
    研究分野別
    免疫学
    微生物学
    脳神経科学
    シグナル伝達
    ステムセル
  • 診断と治療のソリューション
    カスタム・ソリューション & パートナーシップ

    あなたの診断法や治療法を発展させるための、カスタム抗体開発およびコマーシャル・パートナーシップ

    私たちと共にカスタム・ソリューションを創造する

    私たちとパートナーになる

  • サポート
    サポートハブ

    研究のためのサポートとアドバイス

    サポートハブを表示

    プロトコール

    実験のステップごとの詳細

    プロトコールを表示

  • イベント
    • イベント・カレンダー
    • 癌
    • 循環器
    • エピジェネティクス&核内情報
    • 免疫学
    • ニューロサイエンス
    • ステムセル
    • 展示会
    • ウェビナー
    最新のイベント情報

    世界中でアブカムが主催する研究会やセミナーの日程、内容、演者など

    イベント・カレンダー

  • パスウェイ
    細胞シグナル伝達パスウェイ

    すべてのパスウェイを見る

    インタラクティブ・パスウェイを見る

  • ブログ
    アブカム・ブログ

    最新の情報はこちら.

    • キャンペーン
    • 製品情報
    • 技術情報

新型コロナウイルス (COVID-19)に伴う当社の対応について

  1. Link

    recombinant-human-fgfr3-mutated-v443l-protein-his-tag-ab271515.pdf

  1. Send me a copy of this email
    I agree to the terms and conditions.
Cardiovascular Angiogenesis Growth Factors FGF FGF Receptors
Share by email

Recombinant Human FGFR3 (mutated V443L) protein (His tag) (ab271515)

  • Datasheet
Submit a review Submit a question

Product price, shipping and contact information

Currently unavailable

申し訳ございませんが、現在表示できません。

こちらにお問い合わせいただくか、またはしばらく経ってから改めてお試しください

 

Loading size & price…

 

出荷および受注について

Abpromise

保証された製品品質、優れたカスタマー・サポート。 詳細はこちら。

SDS-PAGE - Recombinant Human FGFR3 protein (Tagged) (ab271515)
  • Western blot - Recombinant Human FGFR3 protein (Tagged) (ab271515)

Key features and details

  • Expression system: Baculovirus infected Sf9 cells
  • Tags: His tag N-Terminus
  • Suitable for: SDS-PAGE

こちらの製品もご検討ください

ELISA
Product image
Human FGFR3 ELISA Kit (ab214027)
抗体ペア
Product image
Human FGFR3 Matched Antibody Pair Kit (ab220123)

関連製品

カルタヘナ法

製品の詳細

  • 製品名

    Recombinant Human FGFR3 (mutated V443L) protein (His tag)
    FGFR3 タンパク質・ペプチド 製品一覧
  • 発現系

    Baculovirus infected Sf9 cells
  • アクセッション番号

    P22607
  • タンパク質長

    Protein fragment
  • Animal free

    No
  • 由来

    Recombinant
    • 生物種

      Human
    • 予測される分子量

      37 kDa including tags
    • 領域

      447 to 761
    • 修飾

      mutated V443L
    • タグ

      His tag N-Terminus
    • 配列の追加情報

      Genbank: NM_000142

関連製品

    特性

    Our Abpromise guarantee covers the use of ab271515 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    • アプリケーション

      SDS-PAGE

    • 製品の状態

      Liquid
    • 備考

      Phosphorylation is <10%.

    • Concentration information loading...

    前処理および保存

    • 保存方法および安定性

      Shipped on Dry Ice. Store at -80°C. Avoid freeze / thaw cycle.

      pH: 8.00
      Constituents: 0.63% Tris HCl, 0.64% Sodium chloride, 0.02% Potassium chloride, 0.02% Tween, 20% Glycerol (glycerin, glycerine), 0.05% (R*,R*)-1,4-Dimercaptobutan-2,3-diol

    関連情報

    • 別名

      • ACH
      • CD 333
      • CD333
      • CD333 antigen
      • CEK 2
      • CEK2
      • FGFR 3
      • FGFR-3
      • FGFR3
      • FGFR3_HUMAN
      • Fibroblast growth factor receptor 3
      • Fibroblast growth factor receptor 3 (achondroplasia thanatophoric dwarfism)
      • Heparin binding growth factor receptor
      • HSFGFR3EX
      • Hydroxyaryl protein kinase
      • JTK 4
      • JTK4
      • MFR 3
      • SAM 3
      • Tyrosine kinase JTK 4
      • Tyrosine kinase JTK4
      • Z FGFR 3
      see all
    • 機能

      Receptor for acidic and basic fibroblast growth factors. Preferentially binds FGF1.
    • 組織特異性

      Expressed in brain, kidney and testis. Very low or no expression in spleen, heart, and muscle. In 20- to 22-week old fetuses it is expressed at high level in kidney, lung, small intestine and brain, and to a lower degree in spleen, liver, and muscle. Isoform 2 is detected in epithelial cells. Isoform 1 is not detected in epithelial cells. Isoform 1 and isoform 2 are detected in fibroblastic cells.
    • 関連疾患

      Defects in FGFR3 are the cause of achondroplasia (ACH) [MIM:100800]. ACH is an autosomal dominant disease and is the most frequent form of short-limb dwarfism. It is characterized by a long, narrow trunk, short extremities, particularly in the proximal (rhizomelic) segments, a large head with frontal bossing, hypoplasia of the midface and a trident configuration of the hands.
      Defects in FGFR3 are the cause of Crouzon syndrome with acanthosis nigricans (CAN) [MIM:612247]. Classic Crouzon disease which is caused by mutations in the FGFR2 gene is characterized by craniosynostosis (premature fusion of the skull sutures), and facial hypoplasia. Crouzon syndrome with acanthosis nigricans (a skin disorder characterized by pigmentation anomalies), CAN, is considered to be an independent disorder from classic Crouzon syndrome. CAN is characterized by additional more severe physical manifestation, such as Chiari malformation, hydrocephalus, and atresia or stenosis of the choanas, and is caused by a specific mutation (Ala-391 to Glu) in the transmembrane domain of FGFR3. It is proposed to have an autosomal dominant mode of inheritance.
      Defects in FGFR3 are a cause of thanatophoric dysplasia type (TD) [MIM:187600, 187601]; also known as thanatophoric dwarfism or platyspondylic lethal skeletal dysplasia Sand Diego type (PLSD-SD). TD is the most common neonatal lethal skeletal dysplasia. Affected individuals display features similar to those seen in homozygous achondroplasia. It causes severe shortening of the limbs with macrocephaly, narrow thorax and short ribs. In the most common subtype, TD1, femur are curved, while in TD2, straight femurs are associated with cloverleaf skull. Mutations affecting different functional domains of FGFR3 cause different forms of this lethal disorder.
      Defects in FGFR3 are a cause of hypochondroplasia (HCH) [MIM:146000]. HCH is an autosomal dominant disease and is characterized by disproportionate short stature. It resembles achondroplasia, but with a less severe phenotype.
      Defects in FGFR3 are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences. Note=Somatic mutations can constitutively activate FGFR3.
      Defects in FGFR3 are a cause of cervical cancer (CERCA) [MIM:603956]. A malignant neoplasm of the cervix, typically originating from a dysplastic or premalignant lesion previously present at the active squamocolumnar junction. The transformation from mild dysplastic to invasive carcinoma generally occurs slowly within several years, although the rate of this process varies widely. Carcinoma in situ is particularly known to precede invasive cervical cancer in most cases. Cervical cancer is strongly associated with infection by oncogenic types of human papillomavirus.
      Defects in FGFR3 are the cause of camptodactyly tall stature and hearing loss syndrome (CATSHL syndrome) [MIM:610474]. CATSHL syndrome is an autosomal dominant syndrome characterized by permanent and irreducible flexion of one or more fingers of the hand and/or feet, tall stature, scoliosis and/or a pectus excavatum, and hearing loss. Affected individuals have developmental delay and/or mental retardation, and several of these have microcephaly. Radiographic findings included tall vertebral bodies with irregular borders and broad femoral metaphyses with long tubular shafts. On audiological exam, each tested member have bilateral sensorineural hearing loss and absent otoacoustic emissions. The hearing loss was congenital or developed in early infancy, progressed variably in early childhood, and range from mild to severe. Computed tomography and magnetic resonance imaging reveal that the brain, middle ear, and inner ear are structurally normal.
      Defects in FGFR3 are a cause of multiple myeloma (MM) [MIM:254500]. MM is a malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. Note=A chromosomal aberration involving FGFR3 is found in multiple myeloma. Translocation t(4;14)(p16.3;q32.3) with the IgH locus.
      Defects in FGFR3 are a cause of lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]; also known as Levy-Hollister syndrome. LADDS is a form of ectodermal dysplasia, a heterogeneous group of disorders due to abnormal development of two or more ectodermal structures. LADDS is an autosomal dominant syndrome characterized by aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb segments anomalies. In addition to these cardinal features, facial dysmorphism, malformations of the kidney and respiratory system and abnormal genitalia have been reported. Craniosynostosis and severe syndactyly are not observed.
      Defects in FGFR3 are a cause of keratinocytic non-epidermolytic nevus (KNEN) [MIM:162900]; also known as pigmented moles. Epidermal nevi of the common, non-organoid and non-epidermolytic type are benign skin lesions and may vary in their extent from a single (usually linear) lesion to widespread and systematized involvement. They may be present at birth or develop early during childhood.
      Defects in FGFR3 are a cause of Muenke syndrome (MNKS) [MIM:602849]; also known as Muenke non-syndromic coronal craniosynostosis. MNKS is a condition characterized by premature closure of coronal suture of skull during development (coronal craniosynostosis), which affects the shape of the head and face. It may be uni- or bilateral. When bilateral, it is characterized by a skull with a small antero-posterior diameter (brachycephaly), often with a decrease in the depth of the orbits and hypoplasia of the maxillae. Unilateral closure of the coronal sutures leads to flattening of the orbit on the involved side (plagiocephaly). The intellect is normal. In addition to coronal craniosynostosis some affected individuals show skeletal abnormalities of hands and feet, sensorineural hearing loss, mental retardation and respiratory insufficiency.
      Defects in FGFR3 are a cause of keratosis seborrheic (KERSEB) [MIM:182000]. A common benign skin tumor. Seborrheic keratoses usually begin with the appearance of one or more sharply defined, light brown, flat macules. The lesions may be sparse or numerous. As they initially grow, they develop a velvety to finely verrucous surface, followed by an uneven warty surface with multiple plugged follicles and a dull or lackluster appearance.
    • 配列類似性

      Belongs to the protein kinase superfamily. Tyr protein kinase family. Fibroblast growth factor receptor subfamily.
      Contains 3 Ig-like C2-type (immunoglobulin-like) domains.
      Contains 1 protein kinase domain.
    • 細胞内局在

      Membrane.
    • Target information above from: UniProt accession P22607 The UniProt Consortium
      The Universal Protein Resource (UniProt) in 2010
      Nucleic Acids Res. 38:D142-D148 (2010) .

      Information by UniProt

    画像

    • SDS-PAGE - Recombinant Human FGFR3 protein (Tagged) (ab271515)
      SDS-PAGE - Recombinant Human FGFR3 protein (Tagged) (ab271515)

      SDS-PAGE analysis of ab271515.

    • Western blot - Recombinant Human FGFR3 protein (Tagged) (ab271515)
      Western blot - Recombinant Human FGFR3 protein (Tagged) (ab271515)
      All lanes :

      Lane 1 : ab271515
      Lane 2 : MW markers


      Western blot analysis of ab271515.

    プロトコール

    To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.

    Click here to view the general protocols

    データシートおよび資料

    • Datasheet
  • 参考文献 (0)

    ab271515 を使用した論文を発表された方は、こちらまでお知らせください。データシートに掲載させていただきます。

    ab271515 は論文での使用が確認できていません。

    レビューと Q&A

    Show All レビュー Q&A
    レビューを送る 質問を送る

    There are currently no Customer reviews or Questions for ab271515.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
    For licensing inquiries, please contact partnerships@abcam.com

    技術情報や製品情報をメールで受け取る 登録
    製品・研究分野別
    • 癌
    • 循環器
    • 細胞生物学
    • 発生
    • エピジェネティクス&核内情報
    • 免疫学
    • メタボリズム
    • 感染症
    • ニューロサイエンス
    • シグナル伝達
    • ステムセル
    製品・タイプ別
    • 一次抗体
    • 二次抗体
    • バイオケミカルズ
    • アイソタイプ・コントロール
    • マルチカラー・セレクター
    • キット
    • ローディング・コントロール
    • ライゼート
    • ペプチド
    • タンパク質
    • スライド
    • タグ抗体・細胞マーカー
    • その他試薬
    サービス&サポート
    • サポート
    • よくあるお問い合わせ
    • プロトコール&トラブルシュート
    • ご購入に関して
    • お問い合わせフォーム
    • トレーニング
    アブカムについて
    • 企業ウェブサイト
    • 投資家の皆様へ
    • 企業情報
    • 採用情報
    • アブカムについて
    イベント
    • 展示会
    • カンファレンス
    ブログ

    ブログを読む

    International websites
    • abcam.com
    • abcam.cn

    Join with us

    • LinkedIn
    • facebook
    • Twitter
    • YouTube
    • Terms of sale
    • Website terms of use
    • Cookie policy
    • Privacy policy
    • Legal
    © 1998-2021 Abcam plc. All rights reserved.